Introduction {#S1}
============

Tuberculosis (TB) is a major public health problem in the developing world and an increasing threat in developed countries^[@R1]^. While 2 billion people are estimated to be infected with the TB pathogen, *Mycobacterium tuberculosis*, only \~10% of infected individuals eventually develop active TB^[@R1]^. A majority can contain the pathogen; the infection remains latent and clinical disease never occurs. Case observations, twin studies and mouse models indicate that host genetic factors are important in determining susceptibility to *M. tuberculosis*^[@R2],[@R3]^. Recent genome wide association studies (GWAS) reported two loci on chromosomes 11p13 and 18q11 that contain single nucleotide polymorphisms (SNPs) associated with TB^[@R4],[@R5]^. However, the pathophysiological mechanisms underpinning these genetic associations remain unknown.

Results {#S2}
=======

Genome-wide association study {#S3}
-----------------------------

To identify novel genes associated with susceptibility to TB, we initially studied 5,914 HIV-negative patients with active pulmonary TB confirmed by culture of *M. tuberculosis* from sputum, as well as 6,022 healthy adult controls from Russia (see Methods). We genotyped their DNA samples using Affymetrix Genome-Wide Human SNP Array 6.0. After rigorous quality control procedures (Methods, [Supplementary Figs. 1 and 2](#SD1){ref-type="supplementary-material"}) 5,530 TB patients and 5,607 controls with high quality genotypes at 707,452 SNPs remained (Set 1). We then imputed genotypes at 7,614,862 SNPs into the Set 1 subjects using data from the 1000 Genomes project. We tested these SNPs for association with TB using logistic regression corrected for 4 principal components, and did not observe significant inflation of test statistics (λ~GC~ = 1.10), indicating that our cases and controls are well matched ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}).

We first examined our association results in the context of previously published TB GWAS in two African populations^[@R4],[@R5]^. We did not detect any association at the previously reported 18q11 locus. However, we did see association at the 11p13 locus (rs2057178, *P* = 0.00068, [Supplementary Table 1](#SD2){ref-type="supplementary-material"}), as we reported previously for the overlapping Russian dataset^[@R5]^. This is also consistent with another recently published TB GWAS in the South African population^[@R6]^ and suggests that the 11p13 locus is associated with TB risk in various populations, whereas the 18q11 locus may be population-specific. We next studied candidate genes previously reported to be associated with TB and found weak signals in several genes, including the *HLA-DQA1* region ([Supplementary Table 2](#SD2){ref-type="supplementary-material"}). We then looked for the overlap with published genetic associations in another human mycobacterial infectious disease, leprosy^[@R7],[@R8]^, and in inflammatory bowel disease (IBD) that is known to be enriched with genes involved in defense against mycobacteria^[@R9]^. We found that, except for the MHC region, none of those loci was significantly associated with TB after Bonferroni correction ([Supplementary Tables 3](#SD2){ref-type="supplementary-material"} and [4](#SD3){ref-type="supplementary-material"}).

Our only genome-wide significant TB-associated locus was on chromosome 8q24, where 11 SNPs located in introns of the *ASAP1* gene had *P* \< 5 × 10^−8^ ([Fig. 1](#F1){ref-type="fig"}); the strongest association was at rs2033059 (*P* = 1.1 × 10^−8^). To rule out possible technical artefacts, and to attempt to replicate our discovery, we designed individual Taqman genotyping assays for seven out of the most significantly associated *ASAP1* SNPs. We genotyped these SNPs in Set 1 and, additionally, in 1,085 pulmonary TB patients and 2,865 controls from Russia (Set 2). In the combined analysis of 15,087 subjects in Sets 1 and 2 all seven SNPs showed convincing evidence of association with TB ([Table 1](#T1){ref-type="table"}); the most significant association was at rs4733781 (*P* = 2.6 × 10^−11^). In order to try to identify which of these seven SNPs is likely the functional polymorphism affecting risk to pulmonary TB, we employed a Bayesian fine-mapping approach (Methods). Three SNPs had less than 5% posterior probability of being causal, leaving four likely candidates ([Table 1](#T1){ref-type="table"}), with rs4733781 having the highest posterior (43.6%). This narrowing to four candidates likely represents the limit of genetic resolution in our Russian dataset.

We then analyzed the seven *ASAP1* SNPs in the Ghanaian (971 TB cases and 988 controls) and Gambian (1,306 TB cases and 1,372 controls) GWAS datasets that were published previously^[@R4],[@R5]^ ([Table 2](#T2){ref-type="table"}). Despite that these SNPs were less frequent in the African populations than in Russians, resulting in lower statistical power to detect association, this analysis provided further support for TB association of the *ASAP1* SNPs, e.g. for rs4733781 effects in the Ghanaian and Gambian datasets were similar to those in the Russian dataset (ORs = 0.89, 0.89 and 0.84, respectively; *P*~Ghana+Gambia~ = 0.052 and the overall *P*~Russia+Ghana+Gambia~ = 3.6 × 10^−12^).

Analyses of ASAP1 expression and function {#S4}
-----------------------------------------

The *ASAP1* gene (also known as *AMAP1* or *DDEF1*) encodes an Arf GTPase-activating protein (Arf GAP), a multifunctional scaffold protein that induces hydrolysis of GTP bound to the ADP ribosylation factor family GTP-binding (Arf) proteins^[@R10]^. The Arf and Arf GAP proteins are known to regulate coordinated actin and membrane remodelling^[@R11]^. In NIH 3T3 fibroblasts localization of the ASAP1 protein was associated with focal adhesions, circular dorsal ruffles, podosomes and invadopodia, i.e. large macromolecular complexes that connect intracellular actin cytoskeleton to the extracellular matrix and are important for cell adhesion and migration, as well as invasion of cancer cells^[@R11]^. The transition of a cell from a quiescent to a migratory phenotype is characterized by the dissolution of focal adhesions and the formation of podosomes or invadopodia at the sites of contact with extracellular matrix^[@R12]^. *In vitro* knockdown and reduction of ASAP1 expression in the transformed fibroblast and prostate cancer cell lines has been shown to prevent formation of invadopodia and suppress cell migration and invasiveness^[@R13],[@R14]^. Overexpression of ASAP1 has been associated with metastasis in several cancers^[@R14]-[@R17]^. While invadopodia are found in transformed cells, podosomes are similar structures that are present in several types of normal cells, including macrophages and dendritic cells (DCs)^[@R12]^. These immune cells play critical roles in TB pathogenesis. Thus, the infection is initiated when inhaled *M. tuberculosis* bacilli are phagocytosed by alveolar macrophages, which provide a cellular niche for the expansion of mycobacteria. The onset of adaptive immune response leads to killing of mycobacteria and sterilization of regional lesions^[@R18]^. DCs are crucial for the initiation of the adaptive immunity: infected DCs migrate to the lung-draining lymph nodes and activate T cells^[@R19]^. *M. tuberculosis* is known to inhibit migration as well as other functions of DCs, and the adaptive immunity in TB is delayed compared with other microbial infections^[@R20]-[@R22]^.

The role of ASAP1 in macrophages, DCs and other immune cells has not been studied previously. To investigate it, we initially characterized the *ASAP1* mRNA expression by quantitative reverse transcriptase-PCR (qRT-PCR) in primary leukocytes of healthy donors and found that monocytes, B lymphocytes, CD4+ and CD8+ T lymphocytes and neutrophils express relatively low levels of *ASAP1*. However, when monocytes were differentiated into macrophages or DCs, the expression of *ASAP1* increased ([Fig. 2a](#F2){ref-type="fig"}). We then infected DCs with *Mycobacterium bovis BCG* and found that it led to the reduction of *ASAP1* expression ([Fig. 2a](#F2){ref-type="fig"}). We also analyzed *ASAP1* expression in DCs from 65 subjects that were previously studied using microarrays^[@R23]^. Similar to our results, in this dataset the *ASAP1* level in the *M. tuberculosis*-infected DCs was significantly lower than in non-infected DCs (log~2~ fold change = −0.49, *P*~corrected~ = 2.9 × 10^−18^, ref ^[@R23]^). To study if any of the TB-associated SNPs in the *ASAP1* gene affects its expression, we first analyzed rs10956514 and rs4733781 that were genotyped in this dataset. The SNP rs10956514 showed evidence of association with *ASAP1* expression in non-infected samples (*P* = 4.6 × 10^−3^) and with the relative level of reduction in *ASAP1* expression after *M. tuberculosis* infection (*P* = 4.6 × 10^−3^). Homozygotes of allele A, which was associated with higher TB risk in our GWAS, showed stronger reduction of *ASAP1* expression after infection than homozygotes of allele G, which was associated with lower TB risk ([Fig. 2b](#F2){ref-type="fig"}). We imputed genotypes of other TB-associated *ASAP1* SNPs and found that they had weaker association with the level of reduction of *ASAP1* expression after *M. tuberculosis* infection than rs10956514 ([Supplementary Table 5](#SD2){ref-type="supplementary-material"}). The lack of association between *ASAP1* expression and rs4733781 reflects different linkage disequilibrium patterns in this region (e.g. r^2^ between rs4733781 and rs10956514 was 0.8 in the Russian dataset, but only 0.62 in 65 non-Russian Caucasians^[@R23]^). These results indicate that larger studies in different populations will be needed to pinpoint the causative variant affecting *ASAP1* expression, and thence the risk of pulmonary TB. Nevertheless, our results suggest that either rs10956514 or a polymorphism in strong linkage disequilibrium with it may be responsible for the control of *ASAP1* expression in DCs. Since rs10956514 is also one of the candidates associated with the risk of active pulmonary TB ([Table 1](#T1){ref-type="table"}), genetically regulated levels of *ASAP1* expression in DCs are likely to be important in TB pathogenesis.

To investigate the role of the ASAP1 protein in DCs, we first studied its cellular localization. Confocal microscopy showed that the ASAP1 protein was localized in the cytoplasm and partly was associated with podosomes ([Fig. 3a](#F3){ref-type="fig"}). Therefore, we hypothesized that reduced ASAP1 expression may affect matrix degradation by DCs and their migration. To test this, we isolated primary monocytes from healthy volunteers, derived DCs *in vitro* and transfected them with siRNA to reduce ASAP1 expression. We found that degradation of a gelatine matrix by the ASAP1-depleted DCs was impaired ([Fig. 3b](#F3){ref-type="fig"}) and such cells migrated significantly slower than control cells ([Fig. 3c](#F3){ref-type="fig"}).

Discussion {#S5}
==========

Taken together, our results suggest that impaired migration of *M. tuberculosis*-infected DCs, caused by the genetically determined excessive reduction of *ASAP1* expression, may contribute to TB pathogenesis. It may be one of the mechanisms that lead to the slow migration of DCs to lymph nodes and delay the adaptive immune response during early stages of TB infection. Furthermore, given that latent TB is a state of dynamic equilibrium, it is likely that trafficking of immune cells in granulomas has to be constantly maintained^[@R19]^. Therefore, impaired migration of DCs and/or macrophages due to the reduced *ASAP1* expression may contribute also at late stages of infection leading to reactivation of latent TB.

To date, GWAS of susceptibility to TB and other infectious diseases identified fewer associated loci than studies of other complex diseases. This indicates that effects of common polymorphisms predisposing to infection are usually small, and current GWA studies may be statistically underpowered. In TB, this can be explained by the strong selective pressure exerted by *M. tuberculosis*, an ancient and wide-spread pathogen. Nevertheless, our results demonstrate that when associated variants are found, they can highlight novel molecular mechanisms implicated in infection and host responses. Future studies will further clarify how the ASAP1-mediated pathways are involved in mycobacterial infection and predispose to TB.

Online Methods {#S7}
==============

Ethics {#S8}
------

Blood samples from all participants have been collected and studied with the written informed consent according to the Declaration of Helsinki and with approvals from the local Ethics Committees in Russia (St. Petersburg and Samara), and the UK (Human Biological Resource Ethics Committee of the University of Cambridge and the National Research Ethics Service Cambridgeshire 1 REC, ref 10/H0304/71).

TB patients and controls {#S9}
------------------------

Pulmonary TB patients attending civilian TB dispensaries and TB clinics along with healthy subjects attending the blood transfusion service were recruited in two Russian cities, St. Petersburg and Samara, as described previously^[@R24]^. TB patients have been diagnosed using information about TB contact, medical history and clinical symptoms (cough, haemoptysis, chest pain, fever, weight loss), presence of acid fast bacilli in sputum smear and symptoms characteristic of pulmonary TB on chest X rays. For all patients in this study diagnosis has been confirmed by culture of *M. tuberculosis* from sputum; otherwise patients were excluded. We also excluded from the study patients with extra-pulmonary TB and all HIV-positive subjects. Controls were healthy adult blood bank donors with no history of TB. *M. tuberculosis* infection status of these controls was unknown. We studied genotypes of 15,087 subjects, including 6,615 TB patients (4,074 from St. Petersburg and 2,541 from Samara) and 8,472 controls (5,555 from St. Petersburg and 2,917 from Samara). Average age was 45 years for patients and 31 years for controls. There were 73% of males among patients and 71% of males among controls. This sample size provides \>80% statistical power to detect association with *P* = 5 × 10^−8^ for polymorphisms with minor allele frequencies (MAF) \> 20% and OR \> 1.2.

Genotyping, quality control and association analyses {#S10}
----------------------------------------------------

We extracted genomic DNA from whole blood of the participating subjects using a standard chloroform/proteinase K protocol. We checked DNA quality using 1% agarose gel electrophoresis, determined DNA concentration using Picogreen assay and then normalized concentration for genotyping.

In GWAS, genotyping was done using the Affymetrix Genome-Wide Human SNP Array 6.0. Genotypes were called in 5,914 TB cases and 6,022 controls using Birdseed^[@R25]^. Individuals were excluded if they had more than 2% missing genotype data or showed excess of heterozygous genotypes (±3.5 standard deviations, [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}). For each pair of individuals, we calculated identity-by-state (IBS) and excluded samples with IBS \> 80% as likely duplicates or close relatives. Finally, IBS was also calculated between each sample from this study and 1,397 samples from the International HapMap project. The IBS relationships were converted to distance, and projected onto two axes of multidimensional scaling. We removed non-European ancestry outliers based on these projections ([Supplementary Fig. 2a](#SD1){ref-type="supplementary-material"}). After removing these individuals, we excluded SNPs with a call rate of less than 98%, Hardy-Weinberg *P*-value \< 10^−6^ (in controls), missing rate per SNP difference in cases and controls \> 0.02 or a minor allele frequency less than 1%. In total, 799 individuals and 175,385 SNPs were excluded, leaving for analysis 707,452 SNPs in 5,530 cases and 5,607 controls, which we call Set 1. Principal component analysis was performed across autosomal SNPs within Set 1 ([Supplementary Figs. 2b and 2c](#SD1){ref-type="supplementary-material"}). We computed the first 10 principal components and decided to include the top 4 in our downstream analysis to account for population structure remaining in our dataset.

We imputed SNPs from the 1000 Genomes Phase I (interim) release into our Set 1 samples using IMPUTE2^[@R26],[@R27]^. Imputed SNPs were excluded if the imputation quality score r^2^ was \< 0.5 and minor allele frequency was \< 1%. After filtering, 7,614,862 SNPs were left for further association analyses.

TB association was tested with logistic regression implemented in SNPTEST^[@R28]^ on genotype likelihoods from imputation, with 4 PCs as covariates. The genomic control inflation factor λ~GC~ for SNPs before and after imputation was 1.10 ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}), indicating that we have successfully controlled for any residual population structure between cases and controls.

SNPs from the 1000 Genomes Phase I (interim) release were imputed into Ghanaian and Gambian subjects using IMPUTE2 and TB association of the seven *ASAP1* SNPs was tested with logistic regression implemented in SNPTEST.

We genotyped seven *ASAP1* SNPs using custom Taqman assays ([Supplementary Table 6](#SD2){ref-type="supplementary-material"}) and 7900HT system from Applied Biosystems. We visually checked all genotype clusters, assigned calls and extracted genotypes using SDS 2.3 software. TB association was tested in STATA11 using logistic regression, with the city of the sample origin (St. Petersburg or Samara) as a covariate.

To conduct Bayesian fine-mapping we calculated marginal likelihoods for each SNP and Bayes Factors using a normal prior with mean 0 and variance 0.2. Posterior probabilities were assigned using the relative contribution of each SNP's Bayes Factor to the sum of Bayes Factors across all seven SNPs^[@R29]^.

We analyzed the seven *ASAP1* SNPs in the Ghanaian and Gambian TB GWAS datasets that were published previously^[@R4],[@R5]^. The Gambian dataset is available in the The European Genome-phenome Archive (accession number EGAS00000000027). Both Ghanaian and Gambian datasets have been QCed by filtering individuals with discordant sex information, elevated missing data rates (\>2%), outlying heterozygosity rate (±3.5 standard deviations), duplicated or related individuals with IBS \>80% and divergent ancestry based on principal component projections using the HapMap dataset. In total, 101 (13 cases and 88 controls) and 316 (192 cases and 124 controls) individuals were excluded from Ghanaian and Gambian datasets, respectively. After individual quality control, we imputed the seven *ASAP1* SNPs from the 1000 Genomes Phase I (interim) release into Ghanaian and Gambian samples using IMPUTE2^[@R26],[@R27]^.

Analysis of association between SNPs and levels of *ASAP1* mRNA expression in DCs {#S11}
---------------------------------------------------------------------------------

We analyzed genome-wide expression data from DCs isolated from 65 Caucasian subjects^[@R23]^. These DCs were either non-infected or infected *in vitro* for 18 hours with *M. tuberculosis* and were studied using Illumina HT-12 expression arrays^[@R23]^. The raw data can be obtained from the GEO database (accession numbers GSE34588 and GSE34151). For our analysis, we used a cleaned dataset provided by L. Barreiro (personal communications) in which expression levels were regressed using the first 5 principal components for the data from non-infected cells and the first 8 principal components for the data from infected cells. We used the R package snpStats (D. Clayton, snpStats: snpMatrix and XSnpMatrix classes and methods, R package version 1.12.10) to fit generalized linear models, with SNP genotypes as predictor variables and expression levels of *ASAP1* as responses. We report *P*-values for the two-tailed test where the null hypothesis was that the true value of the generalized linear model coefficient is zero. We imputed genotypes of the *ASAP1* SNPs rs2033059, rs17285138, rs1469288, rs12680942, rs1017281 with the MaCH and minimac software packages^[@R30]^ using genotype data from 1000 Genomes.

Cells and Antibodies {#S12}
--------------------

Human PBMC were isolated from fresh peripheral blood of healthy adult volunteers participating in the Cambridge BioResource cohort by centrifugation of peripheral blood with a gradient of Ficoll-paque Plus (GE Healthcare) at 860 g for 23 minutes at room temperature. Buffy coat layer containing PBMC was used for sequential isolation of monocytes, CD8+ T cells, CD4+ T cells and B cells. Red blood cells (RBCs) and polymorphonuclear cells sediment was used for neutrophil isolation. Monocytes were purified from PBMC using the MACS CD14+ Isolation kit (Miltenyi, UK Cat. No 130-050-201). CD8+ and CD4+ T cells were isolated from PBMCs using immunomagnetic positive selection kits (Stemcells Technologies Cat. No. 18053 and 18052). B cells were isolated from PBMCs using an immunomagnetic negative selection kit (Miltenyi Biotec 130-091-151). To isolate neutrophils, RBCs and granulocytes sediments were incubated with the same volume of fresh cold RBC lysis buffer on ice for 30 minutes and centrifuged for 5 minutes at 200 g. Cell pellets were then suspended with 10 ml of cold RBC lysis buffer and incubated on ice for 10 minutes. Neutrophil pellets were then washed with cold PBS 3 times.

To derive dendritic cells (DCs), the monocytes were cultured for 6 days in RPMI-1640 (Life technologies) with gentamycin (50 μg/ml), 5% FCS, GM-CSF (50 U/ml, Miltenyi, UK) and IL-4 (1000 U/ml, R&D Systems). To derive macrophages, the monocytes were cultured for 5 days in RPMI-1640 with HEPES (0.02 M), gentamycin (50 μg/ml), 10% FCS and 50 ng/ml M-CSF (Miltenyi, UK). Where indicated DCs were infected with live *M. bovis BCG* genetically modified to express mCherry protein (provided by Dr Brian Robertson, Imperial College, UK) at multiplicity of infection 3:1 and then lysed for RNA or protein extraction.

For immunofluorescence the following antibodies were used: anti-ASAP1 antibody (Sc-81896, Santa Cruz Biotechnology), anti-Vinculin antibody (700062, Invitrogen) and Alexa Fluor 568-coupled phalloidin (A12380, Molecular Probes). The secondary antibodies were Alexa Fluor 633-conjugated goat anti-rabbit IgG (Molecular Probes), and Alexa Fluor 488-conjugated donkey anti-mouse IgG (Molecular Probes). For western blots the following antibodies were used: anti-ASAP1 antibody (ab11011, Abcam) and anti-Actin antibody (A5441, Sigma).

qRT-PCR {#S13}
-------

Two-step qRT-PCR was used for analysis of the *ASAP1* mRNA expression in neutrophils, monocytes, CD4+ T cells, CD8+ T cells, B cells, monocyte-derived macrophages and monocyte-derived DCs. Total RNA was isolated from cells using Isolate RNA Mini Kit as per the manufacturer's instructions (Bioline UK, Cat No: BIO-52044). Then the first strand cDNA was generated from 200 ng of total RNA using Thermo Scientific Maxima Reverse Transcriptase (Thermo Scientific, UK, Cat. No. EP0741) and diluted 1:5. Then 2 μl were taken for qPCR using KAPA SYBR FAST Universal qPCR kit (Kapa Biosystems, UK, Cat. No. KK4602), *ASAP1* primers and primers for the beta-2 microglobulin gene ([Supplementary Table 7](#SD2){ref-type="supplementary-material"}). qPCR reactions were done in triplicate. The data were analyzed using delta Ct values, providing *ASAP1* mRNA expression levels relative to the levels of beta-2 microglobulin mRNA.

siRNA transfection {#S14}
------------------

DCs were transfected at day 1 and day 4 using Hiperfect (Qiagen) with either a pool of three *ASAP1*-specific siRNAs ([Supplementary Table 7](#SD2){ref-type="supplementary-material"}) or with a control, scrambled, siRNA (1027281, Qiagen). Western blotting with the anti-ASAP1 antibody (ab11011, Abcam) was done in each case to assess knockdown efficiency. Results were analysed only if in cells treated with the *ASAP1* siRNA expression of the ASAP1 protein was reduced to below 60% of that in cells treated with the control siRNA.

DC matrix degradation assay {#S15}
---------------------------

Cover slips were coated with 0.2 mg/ml FITC-coupled gelatine (G13187, Molecular Probes) and subsequently blocked using complete media. The siRNA-treated cells were seeded on the cover slips and incubated at 37°C for 4 hours and fixed with 4% PFA. The cells were labelled with Alexa Fluor 568-coupled phalloidin (A12380, Molecular Probes) and mounted in anti-fade with DAPI (P36931, Molecular Probes). Cells were imaged on a Leica SP5 confocal microscope. The images were processed using ImageJ (Wayne Rasband, NIH). Matrix degradation was quantified by measuring the area where the FITC labelled-gelatine was below the threshold and counting the number of cells using ImageJ, as described before^[@R31]^.

DC migration assay {#S16}
------------------

The siRNA-treated cells were seeded on cover slips coated with 0.025 mg/ml fibronectin (F1141, Sigma) and incubated at 37°C for 4 hours in their usual media without GM-CSF or IL-4. Cover slips were then inverted onto Dunn chambers containing GM-CSF (100 U/ml). The cells were imaged every 2-4 minutes for a minimum of 2 hours in the 37°C chamber of Leica SPE. Images were processed and analyzed using the manual track plugin of ImageJ and velocity was calculated.
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======================
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![Genome-wide association study of susceptibility to TB\
(**a**) Manhattan plot showing TB association of genotyped and imputed SNPs across the genome. SNPs with *P* \< 5 × 10^−8^ are shown in red.\
(**b**) Regional plot showing SNPs in the *ASAP1* gene region. Circles show *P*-values obtained in GWAS in Set 1; diamonds show *P*-values obtained in the follow-up study of 7 SNPs in Sets 1 and 2 combined. Horizontal line corresponds to *P* \< 5 × 10^−8^. Colors indicate linkage disequilibrium (r^2^) between the most-associated SNP rs4733781 and other SNPs.](emss-62306-f0001){#F1}

![*ASAP1* expression in peripheral blood leukocytes and monocyte-derived macrophages and dendritic cells (DCs)\
(**a**) Levels of the *ASAP1* mRNA expression in primary leukocytes of healthy volunteers each measured in triplicate by quantitative reverse transcriptase PCR and shown relative to the level of expression in monocytes. CD14+ monocytes were isolated from peripheral blood of healthy volunteers and cultured either with M-CSF for 5 days to derive macrophages or with GM-CSF and IL-4 for 6 days to derive DCs. DCs were infected with live *M. bovis BCG* at multiplicity of infection 3:1 for 24 hours. Horizontal bars show mean levels. *P*-values were calculated using two-tailed Student T test. Unadjusted *P*-values are shown.\
(**b**) Box plot showing the level of reduction of *ASAP1* mRNA expression in DCs after *M. tuberculosis* infection for 65 subjects with different rs10956514 genotypes, 23 (AA), 30 (AG) and 12 (GG). The bold line in the boxplot is the median; the whiskers are 1.5 IQR away from the first and third quartiles. Data are from ref ^[@R23]^ after adjustment for 5 and 8 principle components in non-infected and infected DCs, respectively (see Methods).](emss-62306-f0002){#F2}

![In DCs, the ASAP1 protein is partly associated with podosomes and its depletion leads to impaired matrix degradation and migration\
(**a**) Confocal microscopy showing ASAP1 (green), actin (red), vinculin (blue) and nuclei (white) in DCs derived from monocytes of a healthy volunteer. Podosomes are structures characterized by the actin core (visible as red dots) surrounded by other proteins. Boxed area is shown in grayscale enlarged on the right. Scale bar represents 7.5μm.\
(**b**) Representative confocal microscopy images (left panel) showing monocyte-derived DCs treated with either *ASAP1* or control siRNA and seeded on FITC-conjugated gelatine (green) for 4 hours. The cells were stained to visualize actin (phalloidin-red) and nuclei (DAPI-blue). White arrows show examples of the DAPI-stained nuclei of cells that do not degrade matrix. Scale bar represents 50μm.\
In the same experiment cell lysates were collected for western blotting and probed with anti-ASAP1 and anti-actin antibodies (right panel) to assess knockdown efficiency.\
Area of degradation of the FITC-conjugated gelatine matrix by DCs (lower panel). In total 394 and 317 DCs treated with either *ASAP1* or control siRNA, respectively, were counted in 4 independent experiments.\
(**c**) Migration velocity of DCs in a Dunn chamber. In total 162 and 186 DCs treated with either *ASAP1* or control siRNA, respectively, were tracked in 5 independent experiments.\
Graphs show mean values ± SEM. *P*-values were calculated using two-tailed Student T test. Unadjusted *P*-values are shown.](emss-62306-f0003){#F3}

###### Association between the *ASAP1* gene polymorphisms and tuberculosis in the Russian datasets

                                         rs1017281       rs10956514      rs1469288       rs17285138      rs2033059       rs4733781       rs12680942
  -------------------------------------- --------------- --------------- --------------- --------------- --------------- --------------- ---------------
  Set 1 (GWAS set re-typed)                                                                                                              
  n cont.                                5,526           5,503           5,346           5,494           5,266           5,533           5,369
  n cases                                5,466           5,425           5,272           5,420           5,416           5,457           5,314
  *P*-value                              3.7 × 10^−08^   1.9 × 10^−08^   1.4 × 10^−08^   5.6 × 10^−08^   1.6 × 10^−09^   3.6 × 10^−09^   7.6 × 10^−09^
  OR ^[a](#TFN1){ref-type="table-fn"}^   0.85            0.85            0.84            0.85            0.83            0.84            0.84
  95% CI                                 0.81-0.90       0.80-0.90       0.79-0.89       0.80-0.90       0.79-0.88       0.79-0.89       0.79-0.89
                                                                                                                                         
  Set 2 (follow-up)                                                                                                                      
  n cont.                                2,538           2,535           2,390           2,717           2,692           2,549           2,522
  n cases                                970             971             897             1,048           1,038           975             1,030
  *P*-value                              6.6 × 10^−03^   3.5 × 10^−03^   2.3 × 10^−02^   2.2 × 10^−02^   1.7 × 10^−02^   7.8 × 10^−03^   3.5 × 10^−02^
  OR ^[a](#TFN1){ref-type="table-fn"}^   0.85            0.84            0.87            0.88            0.87            0.85            0.88
  95% CI                                 0.76-0.96       0.75-0.95       0.77-0.98       0.78-0.98       0.78-0.98       0.76-0.96       0.79-0.99
                                                                                                                                         
  Sets 1 and 2 combined                                                                                                                  
  n cont.                                8,064           8,038           7,736           8,211           7,958           8,082           7,891
  n cases                                6,436           6,396           6,169           6,468           6,454           6,432           6,344
  *P*-value                              3.7 × 10^−10^   1.0 × 10^−10^   1.1 × 10^−10^   3.3 × 10^−09^   4.3 × 10^−11^   2.6 × 10^−11^   4.1 × 10^−10^
  OR ^[a](#TFN1){ref-type="table-fn"}^   0.85            0.85            0.84            0.86            0.84            0.84            0.85
  95% CI                                 0.81-0.90       0.81-0.89       0.80-0.89       0.82-0.90       0.80-0.89       0.80-0.88       0.81-0.89
                                                                                                                                         
  PPP                                    0.030           **0.108**       **0.118**       0.004           **0.271**       **0.436**       0.033

ORs for minor alleles are shown

cont. -- controls; min. -- minor; maj. -- major; MAF -- minor allele frequency; OR -- odds ratio; 95% CI -- 95% confidence interval; PPP - proportion of posterior probability, SNPs with PPP \> 0.05 are shown in bold.

###### Association between the *ASAP1* gene polymorphisms and tuberculosis in the Ghanaian and Gambian datasets

  minor/major   Ghana   Gambia   Ghana + Gambia                                                                               
  ------------- ------- -------- ------------------ ------ ------ ------------------ ------ ------ ------------------ ------- -------
  rs4733781     C/A     11.6     0.89 (0.73-1.09)   0.26   9.2    0.89 (0.74-1.08)   0.23   10.2   0.89 (0.78-1.02)   0.052   2.636
  rs12680942    G/A     11.9     0.89 (0.73-1.09)   0.26   9.3    0.89 (0.74-1.08)   0.24   10.4   0.89 (0.78-1.03)   0.055   2.547
  rs17285138    A/T     11.8     0.90 (0.73-1.09)   0.28   9.3    0.89 (0.73-1.07)   0.21   10.3   0.89 (0.78-1.02)   0.053   2.612
  rs2033059     T/C     7.3      0.91 (0.71-1.16)   0.47   8.6    0.88 (0.73-1.07)   0.21   8.1    0.89 (0.76-1.04)   0.074   2.085
  rs10956514    G/A     24.5     0.95 (0.82-1.10)   0.48   21.2   1.02 (0.90-1.16)   0.75   22.6   0.99 (0.9-1.09)    0.845   0.038
  rs1017281     A/G     24.2     0.94 (0.82-1.09)   0.45   21.1   1.02 (0.90-1.17)   0.72   22.4   0.99 (0.9-1.09)    0.832   0.045
  rs1469288     A/G     19.9     0.97 (0.83-1.14)   0.74   17.0   0.96 (0.83-1.11)   0.58   18.2   0.97 (0.87-1.08)   0.272   0.367

SNP -- single nucleotide polymorphism; MAF -- minor allele frequency; OR -- odds ratio; 95% CI -- 95% confidence interval

ORs for minor alleles are shown

When ORs in the Russian, Ghanaian and Gambian populations were in the same direction, we used one-tailed χ^2^ test to calculate *P*-values. Otherwise, we used two-tailed χ^2^ test (for SNPs rs10956514 and rs1017281).
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